ArticleClinical pharmacology and therapeutics2015
Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach.
Article in Clinical pharmacology and therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Non-adherence to Statin Treatment: A Narrative Review of Causes, Clinical Impact, and Preventive Strategies.Cureus · 2026Review
- Impact of frailty on rehabilitation exercise adherence in patients with ischemic stroke.Frontiers in medicine · 2025Article
- Translational drug-interaction corpus.Database : the journal of biological databases and curation · 2022Article
- A multistate transition model for statin-induced myopathy and statin discontinuation.CPT: pharmacometrics & systems pharmacology · 2021Article
- A super-combo-drug test to detect adverse drug events and drug interactions from electronic health records in the era of polypharmacy.Statistics in medicine · 2020Article
- Finding Causal Mechanistic Drug-Drug Interactions from Observational Data.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2020Article
- Mining Directional Drug Interaction Effects on Myopathy Using the FAERS Database.IEEE journal of biomedical and health informatics · 2019Article
- Estimating causal log-odds ratio using the case-control sample and its application in the pharmaco-epidemiology study.Statistical methods in medical research · 2019Article
- Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.International journal of molecular sciences · 2018Review
- Translational Biomedical Informatics and Pharmacometrics Approaches in the Drug Interactions Research.CPT: pharmacometrics & systems pharmacology · 2018Review
- Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells.Pharmaceutics · 2017Article
- Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.Epidemiology (Cambridge, Mass.) · 2017Article
- Big Data: Challenges and opportunities for clinical pharmacology.British journal of clinical pharmacology · 2016Article
- Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions.Molecular pharmaceutics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Myopathy is a group of muscle diseases that can be induced or exacerbated by drug-drug interactions (DDIs). We sought to identify clinically important myopathic DDIs and elucidate their underlying mechanisms. Five DDIs were found to increase the risk of myopathy based on analysis of observational data from the Indiana Network of Patient Care. Loratadine interacted with simvastatin (relative risk 95% confidence interval [CI] = [1.39, 2.06]), alprazolam (1.50, 2.31), ropinirole (2.06, 5.00), and omeprazole (1.15, 1.38). Promethazine interacted with tegaserod (1.94, 4.64). In vitro investigation showed that these DDIs were unlikely to result from inhibition of drug metabolism by CYP450 enzymes or from inhibition of hepatic uptake via the membrane transporter OATP1B1/1B3. However, we did observe in vitro synergistic myotoxicity of simvastatin and desloratadine, suggesting a role in loratadine-simvastatin interaction. This interaction was epidemiologically confirmed (odds ratio 95% CI = [2.02, 3.65]) using the data from the US Food and Drug Administration Adverse Event Reporting System.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.